# Reducing Adolescent Suicide Risk: Safety, Efficacy, and Connectome Phenotypes of Intravenous Ketamine

> **NCT04613453** · PHASE2 · TERMINATED · sponsor: **Yale University** · enrollment: 12 (actual)

## Conditions studied

- Adolescent Suicide
- Adolescent Depression

## Interventions

- **DRUG:** Ketamine Infusion
- **DRUG:** Midazolam Infusion

## Key facts

- **NCT ID:** NCT04613453
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-01-21
- **Primary completion:** 2024-07-31
- **Final completion:** 2024-12-03
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Terminated early due to concerns from the NIH DSMB regarding the rate of recruitment and the resulting inability to accomplish the initially approved study aims
- **Last updated:** 2025-08-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04613453

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04613453, "Reducing Adolescent Suicide Risk: Safety, Efficacy, and Connectome Phenotypes of Intravenous Ketamine". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04613453. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*